Table 3 Factors independently associated with LTFU among adult PLHIV on ART in the Tanga region

Age group, years

 15–24

1.51 (1.47–1.55)

1.85 (1.66–2.07)

 25–34

1.22 (1.20–1.25)

1.38 (1.28–1.48)

 35–44

Reference

Reference

 45–54

0.93 (0.91–0.95)

1.03 (0.96–1.11)

 55 + 

1.04 (1.02–1.06)

1.20 (1.11–1.32)

Sex

 Female

Reference

Reference

 Male

0.94 (0.93–0.96)

2.00 (1.51–2.62)

District

 Handeni

1.18 (1.15–1.20)

0.92 (0.83–1.02)

 Kilindi

1.38 (1.33–1.43)

0.58 (0.48–0.70)

 Korogwe

1.29 (1.26–1.32)

0.85 (0.76–0.94)

 Lushoto

1.11 (1.08–1.14)

1.38 (1.25–1.53)

 Mkinga

1.14 (1.02–1.18)

0.41 (0.36–0.46)

 Muheza

2.49 (2.44–2.54)

1.22 (1.12–1.33)

 Pangani

1.22 (1.18–1.26)

2.13 (1.93–2.35)

 Tanga

Reference

references

Pregnant status

 No

Reference

Reference

 Yes

1.10 (1.05–1.16)

0.73 (0.63–0.85)

Marital status

 Cohabiting

0.95 (0.90–1.01)

0.42 (0.35–0.52)

 Divorced

1.01 (0.99–1.04)

1.35 (1.24–1.48)

 Married

Reference

Reference

 Single

1.31 (1.29–1.34)

1.25 (1.17–1.33)

 Widow

1.07 (1.04–1.10)

0.86 (0.76–0.96)

Viral load suppression

 Suppressed

Reference

Reference

 Non-suppressed

2.30 (2.24–2.37)

2.15 (2.02–2.29)

BMI (kg/m²)

 < 18.5

1.95 (1.84–2.07)

1.75 (1.30–2.34)

 18.5–< 25

Reference

Reference

 25–30

1.57 (1.48–1.67)

1.46 (1.10–1.95)

 30 + 

1.60 (1.50–1.68)

1.34 (0.93–1.93)

WHO clinical stage

 I

Reference

Reference

 II

0.01 (0.88–0.92)

1.67 (1.52–1.84)

 III

1.08 (1.06–1.09)

2.51 (2.32–2.72)

 IV

1.18 (1.15–1.21)

2.24 (2.02–2.49)

Drug type

 First-line

Reference

Reference

 Second-line

1.13 (1.09–1.18)

1.19 (0.84–1.69)

Adherence

 Good

Reference

Reference

 Poor

1.75 (1.69–1.82)

1.50 (1.23–1.75)

ART duration

 ≤ 1

1.10 (1.08–1.12)

0.72 (0.65–0.81)

 > 1

Reference

Reference

TB history

 No

Reference

Reference

 Yes

1.92 (1.79–2.05)

1.19 (0.84–1.69)

DTG-related drug

 No

5.80 (4.98–6.64)

7.51 (5.88–10.79)

 Yes

Reference

Reference